Q&A: Senesco's SNS01-T as a new approach to treating B-cell cancers that can be modified for all cancers

Shares of emerging micro-cap Senesco Technologies (NYSE MKT: SNT) have started to wake up after they reported on Monday on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology. The firm is not your typical biotech firm...

New York, 05/06/2012 (informazione.news - comunicati stampa - varie)

Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to:

http://biomedreports.com/fdacal.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

####

About BioMedReports.Com

BioMedReports is a news and research portal covering financial biomedical news and the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. They sell a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release is available at BioMedReports.Com

Media Contacts Only:
Mary Davila,   Assistant Editor, BioMedReports.Com
e-mail: info@biomedreports.com Tel: +1 323 472 4480 Fax: +1 888 210 3556

Copyright Thomson Reuters


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: %s via Thomson Reuters ONE